Company type | Public |
---|---|
NYSE: STJ | |
Industry | Medical devices |
Founded | Saint Paul, Minnesota, 1976 |
Founder | Manuel A. Villafana |
Defunct | January 4, 2017 |
Fate | Acquired by Abbott Laboratories |
Headquarters | |
Area served | Worldwide |
Key people | Michael T. Rousseau, chairman, president and chief executive officer John C. Heinmiller, executive vice president Michael T. Rousseau, chief operating officer Donald J. Zurbay, vice president of finance and chief financial officer |
Products | Cardiac rhythm management devices Implantable cardioverter-defibrillators Neuromodulation devices |
Revenue | $5.6 billion (2014) [1] |
Total assets | $10.207 billion (2014) [1] |
Total equity | $4.2 billion (2014) [1] |
Number of employees | 18,000[2] |
Website | www |
St. Jude Medical, Inc. was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries.[3][4] Its major markets include the United States, Europe, Latin America and Asia-Pacific. The company was named after Jude the Apostle, the patron saint of lost causes.[4]
St. Jude Medical was founded in 1976 and went public in 1977,[4][5] and the company has been listed in the Fortune 500 every year since 2010.[6] The company was acquired by Abbott Laboratories in January 2017.[7][8]
Michael T. Rousseau served as the company's president and chief executive officer from 2016 until its acquisition by Abbott.[9]